Sarepta's Elevidys Sales Surge Amid FDA Expansion, Vesleteplirsen Discontinued

The FDA's decision to expand the approval of Sarepta Therapeutics' Elevidys has significantly boosted its market potential and sales performance. Initially approved for ambulatory boys ages 4 and 5 with Duchenne muscular dystrophy (DMD) in June 2023, the expanded approval now covers all DMD patients aged 4 and older, thereby including non-ambulatory patients as well. This broader approval has accelerated patient uptake, which is reflected in Elevidys generating $181 million in the third quarter alone, greatly surpassing sales forecasts and previous figures[1][3]. The expanded label has allowed the therapy to tap into a larger segment of the DMD market, contributing to Sarepta's overall revenue increase amidst the discontinuation of other therapies like vesleteplirsen[2].